BTK and neoplasm: In addition, other strategies have been shown to convert TAMs to an M1 phenotype and include Bruton's tyrosine kinase (BTK) inhibitors (196), TLR agonists (197), STAT3 inhibitors (198), IL-1Ra inhibitors (199), and LILRB2 inhibitors (200) Taken together, strategies to deplete or inhibit suppressive TAM functions or activate anti-tumor TAMs combined with chemotherapy and/or immunotherapy may have a great potential for the treatment of breast cancer patients.